SCHEMBL4011368

SCHEMBL4011368

Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](C(O)S(N)(=O)=O)[C@@H](O)[C@H]1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA4 P22748 1/20 0.64
CA9 Q16790 1/20 0.64
ADORA3 P0DMS8 8/20 0.63
ADORA2A P29274 3/20 0.55
ADORA1 P30542 3/20 0.55
ADORA2B P29275 2/20 0.55
DNMT1 P26358 1/20 0.53
DNMT3B Q9UBC3 1/20 0.53
SARS1 P49591 1/20 0.53
PDE2A O00408 1/20 0.53
ADRA1A P35348 1/20 0.53
PDE4D Q08499 1/20 0.53
PDE3A Q14432 1/20 0.53
NT5E P21589 3/20 0.52
CD99 P14209 1/20 0.52
P2RY1 P47900 4/20 0.51
P2RY11 Q96G91 2/20 0.51
IARS1 P41252 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10619720 0.88 CA1 (0.49) CA1CA2CA4CA9ADORA3
SCHEMBL11517589 0.84 ADORA3 (0.65) CA1CA2CA4CA9ADORA3
SCHEMBL11517600 0.84 ADORA3 (0.65) CA1CA2CA4CA9ADORA3
SCHEMBL4010175 0.84 AHCY (0.64) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL11519330 0.81 ADORA3 (0.63) CA1CA2CA4CA9ADORA3
SCHEMBL2460500 0.79 P2RY1 (0.58) CA1CA2CA4CA9ADORA3
SCHEMBL258935 0.79 ADORA3 (0.59) CA1CA2CA4CA9ADORA3
SCHEMBL2489469 0.78 CA1 (1.00) CA1CA2CA4CA9ADORA3
SCHEMBL2489474 0.78 CA1 (1.00) CA1CA2CA4CA9ADORA3
SCHEMBL29737838 0.78 CA1 (1.00) CA1CA2CA4CA9ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
EP-2074126-A2 SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF Wyeth a Corporation of the State of Delaware (US) 2009-07-01 EP disclosed
US-20080096903-A1 SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF WYETH (US) 2008-04-24 US disclosed
WO-2008049105-A2 SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF WYETH (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096903-A1 SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 CA1 4466/4885CA2 4557/4885CA4 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.